Literature DB >> 31058493

KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors.

Blake T Riley1, Olga Ilyichova1, Simon J de Veer2, Joakim E Swedberg2, Emily Wilson1, David E Hoke1, Jonathan M Harris3, Ashley M Buckle1.   

Abstract

Sunflower trypsin inhibitor (SFTI-1) is a 14 amino acid serine protease inhibitor. The dual antiparallel β-sheet arrangement of SFTI-1 is stabilized by an N-terminal-C-terminal backbone cyclization and a further disulfide bridge to form a final bicyclic structure. This constrained structure is further rigidified by an extensive network of internal hydrogen bonds. Thus, the structure of SFTI-1 in solution resembles the protease-bound structure, reducing the entropic penalty upon protease binding. When cleaved at the scissile bond, it is thought that the rigidifying features of SFTI-1 maintain its structure, allowing the scissile bond to be reformed. The lack of structural plasticity for SFTI-1 is proposed to favor initial protease binding and continued occupancy in the protease active site, resulting in an equilibrium between the cleaved and uncleaved inhibitor in the presence of a protease. We have determined, at 1.15 Å resolution, the X-ray crystal structures of complexes between human kallikrein-related peptidase 4 (KLK4) and SFTI-FCQR(Asn14) and between KLK4 and an acyclic form of the same inhibitor, SFTI-FCQR(Asn14)[1,14], with the latter displaying a cleaved scissile bond. Structural analysis and MD simulations together reveal the roles of the altered contact sequence, intramolecular hydrogen bonding network, and backbone cyclization in altering the state of SFTI's scissile bond ligation at the protease active site. Taken together, the data presented reveal insights into the role of dynamics in the standard-mechanism inhibition and suggest that modifications on the non-contact strand may be a useful, underexplored approach for generating further potent or selective SFTI-based inhibitors against members of the serine protease family.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31058493     DOI: 10.1021/acs.biochem.9b00191

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Crystal structure of the inhibitor-free form of the serine protease kallikrein-4.

Authors:  Blake T Riley; David E Hoke; Sheena McGowan; Ashley M Buckle
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2019-07-16       Impact factor: 1.056

2.  Rational domestication of a plant-based recombinant expression system expands its biosynthetic range.

Authors:  Mark A Jackson; Lai Yue Chan; Maxim D Harding; David J Craik; Edward K Gilding
Journal:  J Exp Bot       Date:  2022-10-18       Impact factor: 7.298

Review 3.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

Review 4.  Bowman-Birk Inhibitors: Insights into Family of Multifunctional Proteins and Peptides with Potential Therapeutical Applications.

Authors:  Agata Gitlin-Domagalska; Aleksandra Maciejewska; Dawid Dębowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-25

5.  Directed Evolution-Driven Increase of Structural Plasticity Is a Prerequisite for Binding the Complement Lectin Pathway Blocking MASP-Inhibitor Peptides.

Authors:  Zsolt Dürvanger; Eszter Boros; Zoltán Attila Nagy; Rózsa Hegedüs; Márton Megyeri; József Dobó; Péter Gál; Gitta Schlosser; Annamária F Ángyán; Zoltán Gáspári; András Perczel; Veronika Harmat; Gábor Mező; Dóra K Menyhárd; Gábor Pál
Journal:  ACS Chem Biol       Date:  2022-04-04       Impact factor: 4.634

6.  Structural studies of complexes of kallikrein 4 with wild-type and mutated forms of the Kunitz-type inhibitor BbKI.

Authors:  Mi Li; Jaroslav Srp; Michael Mareš; Alexander Wlodawer; Alla Gustchina
Journal:  Acta Crystallogr D Struct Biol       Date:  2021-07-29       Impact factor: 5.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.